The clinician education modules developed can help in overcoming clinical inertia, support clinicians in providing guideline-based LLT, and enable patients to achieve recommended LDL-C levels.

Identification of coronary calcium in selected patients is the single best noninvasive imaging modality to identify future ASCVD risk and inform lipid-lowering therapy decision-making.

In a large, diverse cohort of US patients with the severe hypercholesterolemia phenotype, we identified several patient characteristics associated with increased 9-year all-cause mortality. A significant survival benefit was conferred by lipid-lowering therapy.

High triglyceride and low high-density lipoprotein cholesterol levels, the 2 dyslipidemia-related components of metabolic syndrome, are associated with a higher incidence of clinical HCM.

Digital medicine can aid to move forward towards P5 medicine, in terms of prediction through the collection of big data and AI, prevention through monitoring of patient characteristics, and personalized and participatory by involving the patient when carrying wearable devices.

In this European study, poor LDL-C control was seen across all cohorts, with LDL-C goal attainment rates of 32%, 10%, and 18% for high-risk CV, ASCVD equivalent, and ASCVD cohorts, respectively.

At-risk women benefit similarly to lipid-lowering and other preventive therapies as men but are less likely to be treated.

Site-specific genome editing systems are exciting, inspiring, and promising. With continuous improvement of delivery vehicles, enzymes, and repair pathways in their accuracy, specificity, and efficiency, the scope of their applications in inherited diseases such as heterozygous familial hypercholesterolemia will expand.

Overall, 9 trials comprising 17,226 patients were included. Treatment with statins was related to an increased risk of hemorrhagic stroke versus placebo (RR: 1.57, 95% CrI: 1.13-2.21).

A group of international researchers showed that the full achievement of European Atherosclerosis Society/European Society of Cardiology LDL‐C goals should require a lower threshold for PCSK9 inhibitor initiation and eventually combination of multiple lipid‐lowering therapies.

The risk of a hemorrhagic stroke associated with statin therapy in patients without a history of cerebrovascular disease is nonsignificant, and achieving very low levels of low-density lipoprotein cholesterol does not increase that risk.

Overall, this meta-analysis demonstrates that statin medication is considerably helpful in reducing aneurysm diameter size and aneurysmal growth rate in individuals with aortic aneurysm.

Because cholesterol is important for development and adequate function of the brain, there is a concern that lowering cholesterol in children may affect mental ability. In this study, researchers tested whether treating children with evolocumab for 80 weeks affected mental ability in performing several tasks.

PCSK9 inhibition ameliorated the severity of EAM mice by reducing Th17 cell differentiation. PCSK9 is a promising target for treating myocarditis.

These findings provide real-world evidence that evolocumab use is in accordance with its international guideline-recommended place in dyslipidemia therapy, as well as confirmation of its effectiveness and safety in a heterogeneous population. Evolocumab can address a healthcare gap in the management of dyslipidemia by increasing the...

This study reveals a novel protective mechanism by which PCSK9 inhibition enhances autophagy and thereby reduces oxidative stress and inflammation in atherosclerosis.

Anti-PCSK9 mAb are a safe and effective therapeutic option for lowering LDL-C levels in FH patients. It allowed a significant portion of our FH patients to reach their lipid targets, mainly in those with combined therapy with statin and/or ezetimibe.

The early initiation of PCSK9 inhibitors can significantly reduce the LDL-C and Lp(a) levels in ACS CHIPs-PCI. However, further studies are needed to confirm whether PCSK9 inhibitors can reduce the incidence of CV disease in CHIPs.

Our data agree with the large evidence on the effectiveness/tolerability of PCSK9i therapy; however, although PCSK9i represents a good cholesterol-lowering therapeutic option, our study shows a progressive increase in MACEs during the late follow-up that deserve further research.

There is the question of whether combination therapy should be used as the first step to maximise the effectiveness of the pharmacological approach, avoiding the stepwise approach, which is likely to have a detrimental effect on adherence. Given the ever-changing landscape and the availability of new drugs targeting other important lipids,...